Segment and Other Information (Tables)

12 Months Ended

Aug. 28, 2025


For the year ended 2025	CMBU		CDBU		MCBU		AEBU		All Other		Unallocated		Total

Revenue	$	13,524	$	7,229	$	11,859	$	4,753	$	13	$	—	$	37,378
Cost of goods sold	5,867		3,995		8,650		3,566		14		413		22,505
Gross margin	7,657		3,234		3,209		1,187		(1)		(413)		14,873

Research and development	1,315		864		836		435		—		348		3,798
Selling, general, and administrative	213		188		390		195		—		219		1,205
Restructure and asset impairment	—		—		—		—		—		39		39
Other operating (income) expense, net	—		2		2		—		—		57		61
Operating income (loss)	$	6,129	$	2,180	$	1,981	$	557	$	(1)	$	(1,076)	$	9,770


For the year ended 2024	CMBU		CDBU		MCBU		AEBU		All Other		Unallocated		Total

Revenue	$	3,792	$	4,984	$	11,667	$	4,631	$	37	$	—	$	25,111
Cost of goods sold	2,677		3,638		10,222		3,598		20		(657)		19,498
Gross margin	1,115		1,346		1,445		1,033		17		657		5,613

Research and development	769		960		994		425		—		282		3,430
Selling, general, and administrative	107		139		485		186		(1)		213		1,129
Restructure and asset impairment	—		—		—		—		—		1		1
Other operating (income) expense, net	(5)		(8)		(33)		(10)		—		(195)		(251)
Operating income (loss)	$	244	$	255	$	(1)	$	432	$	18	$	356	$	1,304


For the year ended 2023	CMBU		CDBU		MCBU		AEBU		All Other		Unallocated		Total

Revenue	$	1,872	$	2,124	$	7,394	$	4,139	$	11	$	—	$	15,540
Cost of goods sold	1,801		1,967		9,072		2,905		4		1,207		16,956
Gross margin	71		157		(1,678)		1,234		7		(1,207)		(1,416)

Research and development	755		622		1,122		389		—		226		3,114
Selling, general, and administrative	90		104		414		176		(1)		137		920
Restructure and asset impairment	—		—		—		—		—		171		171
Other operating (income) expense, net	(6)		(6)		(25)		(11)		—		172		124
Operating income (loss)	$	(768)	$	(563)	$	(3,189)	$	680	$	8	$	(1,913)	$	(5,745)

The table below presents the unallocated amounts:


For the year ended	2025		2024		2023

Unallocated
Cost of goods sold:
Stock-based compensation	$	409	$	312	$	201
Provision to write down inventories to net realizable value	—		—		1,831
Lower costs from sale of inventory written down in prior periods	—		(987)		(844)
Other	4		18		19
	413		(657)		1,207
Research and development:
Stock-based compensation	347		296		226
Other	1		(14)		—
	348		282		226
Selling, general, and administrative:
Stock-based compensation	219		213		137

Restructure and asset impairment:	39		1		171

Other operating (income) expense, net:
Patent license charges	57		—		—
Goodwill impairment	—		—		101
Litigation settlement	—		—		68
Patent cross-license agreement gain	—		(200)		—
Other	—		5		3
	57		(195)		172

Total unallocated amounts	$	1,076	$	(356)	$	1,913

Depreciation and amortization expense included in operating income (loss) was as follows: